GlaxoSmithKlineGlaxoSmithKline has been working closely with governments around the world to respond to their pandemic needs since the start of the H1N1 pandemic. We recognise that pandemics are unpredictable and that government needs and plans have evolved as understanding of the H1N1 pandemic has increased. We are committed to working with them to respond their needs as the pandemic evolves and find appropriate and fair solutions.

GlaxoSmithKline KK (GSK) in Japan confirmed that it has reached an agreement with the Government of Japan (Ministry of Health, Labour and Welfare) to amend its existing contract to receive approximately 68 per cent of the ordered vaccine.

The Company is currently in ongoing discussions with a number of governments worldwide regarding their specific pandemic planning needs, including governments who are changing their planned immunization programs.

Pandemics by their nature are unpredictable and we recognize that governments’ needs are changing. We are committed to finding fair solutions for governments changing their immunization programs.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit